{"log_id": 2829205526986618591, "direction": 0, "words_result_num": 56, "words_result": [{"probability": {"variance": 0.000258, "average": 0.993585, "min": 0.917579}, "location": {"width": 593, "top": 217, "height": 37, "left": 196}, "words": "序)、干扰他人。对于混合型,应符台注意力不集中和多动冲动的标准"}, {"probability": {"variance": 0.00083, "average": 0.981788, "min": 0.915528}, "location": {"width": 178, "top": 262, "height": 33, "left": 197}, "words": "综合治疗计划的需要:"}, {"probability": {"variance": 0.001489, "average": 0.990883, "min": 0.757833}, "location": {"width": 718, "top": 292, "height": 39, "left": 236}, "words": "对于这种病症的患者,盐酸托莫西汀是ADHD整体治疗计划的一部分,还应包括其他"}, {"probability": {"variance": 0.000369, "average": 0.993759, "min": 0.879699}, "location": {"width": 753, "top": 329, "height": 41, "left": 200}, "words": "方法(心理的、教育的、社会的)对于本病症,药物治疗可能不适合于所有患本病症的患"}, {"probability": {"variance": 0.002278, "average": 0.988351, "min": 0.69873}, "location": {"width": 756, "top": 367, "height": 41, "left": 200}, "words": "者。药物治疗不适用于ADHD症状继发于环境因素和或其他原发性精神疾病(包括精神"}, {"probability": {"variance": 0.000225, "average": 0.993179, "min": 0.925262}, "location": {"width": 757, "top": 406, "height": 40, "left": 198}, "words": "病)的患者。对于被诊断为该病的儿童和青少年,进行适当的教育是必要的,心理社会干"}, {"probability": {"variance": 0.000749, "average": 0.991906, "min": 0.837364}, "location": {"width": 757, "top": 442, "height": 43, "left": 199}, "words": "预常有帮助。当单独的治疗方法不充分时,医生要根据患者症状持续的时间和程度对其进"}, {"probability": {"variance": 0, "average": 0.999933, "min": 0.999869}, "location": {"width": 96, "top": 498, "height": 24, "left": 202}, "words": "行药物治疗"}, {"probability": {"variance": 3e-06, "average": 0.997528, "min": 0.995678}, "location": {"width": 80, "top": 536, "height": 25, "left": 201}, "words": "长期用药"}, {"probability": {"variance": 0.004667, "average": 0.979598, "min": 0.581733}, "location": {"width": 717, "top": 558, "height": 41, "left": 240}, "words": "尚无盐酸托莫西汀在儿童/青少年(超过9周)和成人ADHD(超过10周)治疗中长"}, {"probability": {"variance": 0.003087, "average": 0.985211, "min": 0.664545}, "location": {"width": 685, "top": 596, "height": 43, "left": 203}, "words": "期疗效的对照研究数据。因此,医生应定期对每个患者长期用药的疗效进行再评价"}, {"probability": {"variance": 6.3e-05, "average": 0.996067, "min": 0.978304}, "location": {"width": 106, "top": 649, "height": 26, "left": 201}, "words": "【不良反应】"}, {"probability": {"variance": 5.2e-05, "average": 0.995568, "min": 0.979624}, "location": {"width": 116, "top": 689, "height": 25, "left": 205}, "words": "临床试验经验"}, {"probability": {"variance": 0.008788, "average": 0.974683, "min": 0.402705}, "location": {"width": 712, "top": 709, "height": 43, "left": 239}, "words": "临床试验中5382名儿童或青少年ADHD患者及1007名成人ADHD患者服用本品ADH"}, {"probability": {"variance": 7e-05, "average": 0.995945, "min": 0.965569}, "location": {"width": 737, "top": 747, "height": 45, "left": 203}, "words": "临床试验期间,1625名儿童和青少年治疗一年以上,2529名儿童和青少年治疗超过6个月"}, {"probability": {"variance": 4.1e-05, "average": 0.997097, "min": 0.962496}, "location": {"width": 715, "top": 799, "height": 45, "left": 247}, "words": "由于开展临床试验的条件差异较大,所以不能将一种药物在临床试验中观察到的不良"}, {"probability": {"variance": 0.012413, "average": 0.964141, "min": 0.408956}, "location": {"width": 754, "top": 834, "height": 53, "left": 205}, "words": "反应率与另一种药物在临床试验中观察到的不良反应率直接进行比较可能无法映"}, {"probability": {"variance": 1e-06, "average": 0.998751, "min": 0.996428}, "location": {"width": 215, "top": 890, "height": 30, "left": 208}, "words": "中所观察到的不良反应率"}, {"probability": {"variance": 0.034973, "average": 0.80417, "min": 0.546345}, "location": {"width": 163, "top": 874, "height": 43, "left": 771}, "words": "礼贸易"}, {"probability": {"variance": 1.5e-05, "average": 0.997702, "min": 0.986488}, "location": {"width": 192, "top": 933, "height": 30, "left": 212}, "words": "儿童和青少年临床试验"}, {"probability": {"variance": 0.013102, "average": 0.891214, "min": 0.730061}, "location": {"width": 209, "top": 886, "height": 81, "left": 788}, "words": "有限公司"}, {"probability": {"variance": 0.001149, "average": 0.989155, "min": 0.819626}, "location": {"width": 741, "top": 919, "height": 94, "left": 248}, "words": "儿童和青少年临床试验中因不良反应引起停药的原因一儿童和青少年急安"}, {"probability": {"variance": 0.015687, "average": 0.938571, "min": 0.352626}, "location": {"width": 409, "top": 1007, "height": 39, "left": 213}, "words": "试验中,3.0%(48/1613)的托莫西汀患者和1.49"}, {"probability": {"variance": 0.000166, "average": 0.993207, "min": 0.95902}, "location": {"width": 298, "top": 996, "height": 35, "left": 671}, "words": "45)的安慰剂患者因不良反应而停"}, {"probability": {"variance": 0.002447, "average": 0.975866, "min": 0.72893}, "location": {"width": 758, "top": 1035, "height": 50, "left": 212}, "words": "药。全部研究中(包括开放研究和长期研究),6.3%强代谢型(EM)患者和112%弱代谢"}, {"probability": {"variance": 0.003258, "average": 0.972565, "min": 0.785508}, "location": {"width": 757, "top": 1074, "height": 48, "left": 214}, "words": "型PM)患者因一种不良反应而停药、本品治疗的患者中,超过1名患者报告因易怒"}, {"probability": {"variance": 0.01073, "average": 0.944333, "min": 0.57445}, "location": {"width": 247, "top": 1118, "height": 26, "left": 553}, "words": "攻击性(0.2%,N=4)、恶心"}, {"probability": {"variance": 0, "average": 0.999593, "min": 0.999593}, "location": {"width": 21, "top": 1113, "height": 19, "left": 949}, "words": "呕"}, {"probability": {"variance": 0, "average": 0.990062, "min": 0.990062}, "location": {"width": 19, "top": 1134, "height": 18, "left": 294}, "words": "N"}, {"probability": {"variance": 0.007083, "average": 0.939287, "min": 0.769774}, "location": {"width": 134, "top": 1125, "height": 26, "left": 367}, "words": "嗜睡(0.3%0,N"}, {"probability": {"variance": 0.000473, "average": 0.984363, "min": 0.932029}, "location": {"width": 94, "top": 1165, "height": 22, "left": 384}, "words": "腹痛(0.2%"}, {"probability": {"variance": 0.014616, "average": 0.908666, "min": 0.667503}, "location": {"width": 88, "top": 1160, "height": 21, "left": 575}, "words": "便秘(0.1"}, {"probability": {"variance": 6e-05, "average": 0.989317, "min": 0.981554}, "location": {"width": 40, "top": 1153, "height": 22, "left": 762}, "words": "疲劳"}, {"probability": {"variance": 0.043272, "average": 0.861734, "min": 0.46235}, "location": {"width": 96, "top": 1149, "height": 22, "left": 876}, "words": "N=2、感"}, {"probability": {"variance": 0, "average": 0.997709, "min": 0.997709}, "location": {"width": 19, "top": 1170, "height": 18, "left": 314}, "words": "N"}, {"probability": {"variance": 3e-06, "average": 0.998581, "min": 0.995945}, "location": {"width": 58, "top": 1206, "height": 23, "left": 219}, "words": "觉异常"}, {"probability": {"variance": 0.000693, "average": 0.972847, "min": 0.946527}, "location": {"width": 40, "top": 1202, "height": 21, "left": 425}, "words": "头痛"}, {"probability": {"variance": 0.043623, "average": 0.867331, "min": 0.447079}, "location": {"width": 114, "top": 1195, "height": 23, "left": 539}, "words": "N-2)而停药"}, {"probability": {"variance": 0.018409, "average": 0.945589, "min": 0.459664}, "location": {"width": 719, "top": 1233, "height": 51, "left": 254}, "words": "癫痫发作一本品尚亲在儿料癫感者中进行过系统评估,这是因为上市之前测试产品"}, {"probability": {"variance": 0.007667, "average": 0.970135, "min": 0.525345}, "location": {"width": 754, "top": 1272, "height": 49, "left": 220}, "words": "的临床试验中将这些患者排除。临床开发计划中,0.2%1125073)的儿童出现癫痫,平均"}, {"probability": {"variance": 0.017493, "average": 0.949352, "min": 0.429347}, "location": {"width": 645, "top": 1313, "height": 45, "left": 221}, "words": "年龄10岁(范围616岁临床试验中弱代谢型患者痛风险为0.3%(1/29"}, {"probability": {"variance": 0.014184, "average": 0.915541, "min": 0.747112}, "location": {"width": 62, "top": 1312, "height": 24, "left": 915}, "words": "商强代"}, {"probability": {"variance": 0, "average": 0.999732, "min": 0.999388}, "location": {"width": 107, "top": 1325, "height": 45, "left": 968}, "words": "州医药"}, {"probability": {"variance": 0.022071, "average": 0.920734, "min": 0.483551}, "location": {"width": 227, "top": 1365, "height": 31, "left": 220}, "words": "谢型患者的微痫风险为0.2%"}, {"probability": {"variance": 0.047648, "average": 0.81958, "min": 0.421452}, "location": {"width": 134, "top": 1365, "height": 33, "left": 936}, "words": "率限公司"}, {"probability": {"variance": 0.00721, "average": 0.981507, "min": 0.483492}, "location": {"width": 723, "top": 1372, "height": 54, "left": 258}, "words": "儿童和青少年安慰剂对照试验中的常见不良反应一表2列出了与服用本品相关发生率"}, {"probability": {"variance": 0.001392, "average": 0.982865, "min": 0.84886}, "location": {"width": 758, "top": 1404, "height": 50, "left": 222}, "words": "2%或更高)且在安慰剂治疗患者中未见相应发生率的常见不良反应(托莫西汀组发生大"}, {"probability": {"variance": 0.026715, "average": 0.916273, "min": 0.589426}, "location": {"width": 88, "top": 1456, "height": 22, "left": 225}, "words": "于安慰剂红"}, {"probability": {"variance": 0.00103, "average": 0.972592, "min": 0.922029}, "location": {"width": 264, "top": 1444, "height": 33, "left": 356}, "words": "除了表3中根据统计意义 Breslc"}, {"probability": {"variance": 0.003538, "average": 0.980552, "min": 0.751893}, "location": {"width": 300, "top": 1434, "height": 33, "left": 672}, "words": "测试选择的某些特定不良反应的BI"}, {"probability": {"variance": 0.002423, "average": 0.985089, "min": 0.699565}, "location": {"width": 748, "top": 1461, "height": 50, "left": 228}, "words": "及QD试验结果外,其他BID试验与QD试验的结果均相似。托莫西汀治疗组患者最常见"}, {"probability": {"variance": 0.018695, "average": 0.935665, "min": 0.419662}, "location": {"width": 742, "top": 1491, "height": 50, "left": 225}, "words": "的不良反应(发生率5%或更高,至少是安慰剂组的2倍,B给药或QD给药)为"}, {"probability": {"variance": 0.017753, "average": 0.846548, "min": 0.713306}, "location": {"width": 120, "top": 1536, "height": 37, "left": 917}, "words": "礼實"}, {"probability": {"variance": 0.041533, "average": 0.808115, "min": 0.52553}, "location": {"width": 124, "top": 1580, "height": 56, "left": 591}, "words": "有限公"}, {"probability": {"variance": 0.000254, "average": 0.982507, "min": 0.965989}, "location": {"width": 225, "top": 1567, "height": 42, "left": 869}, "words": "有限公司"}, {"probability": {"variance": 0.042646, "average": 0.875112, "min": 0.517512}, "location": {"width": 110, "top": 1588, "height": 38, "left": 1063}, "words": "双供存档"}], "language": 3}